-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US17240Y1091 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | 1B |
|---|---|
| PE Ratio | None |
| Target Price | 41 |
| Dividend Yield | 0.0% |
| Beta | nan |
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts. As of February 23, 2023, CinCor Pharma, Inc. operates as a subsidiary of AstraZeneca Finance and Holdings Inc..
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for CINC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026